Moreover, several studies have shown that PPARγ activation can prevent the progression of hepatic steatosis in murine models [46], and that treatment with the PPARγ agonist rosiglitazone exerts similar effects [47]. The gene discussed is PPARG; the disease is fatty liver disease.